Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
Date:4/25/2013

additional research funding, of which we will recognize $1.7 million of this amount in 2013 and the remaining portion will be recognized as revenue between 2014 and July 2016.  The extended collaboration was generally contemplated in our original 2013 guidance and we are therefore confirming our guidance," Rogers added.

For the full year 2013, Senomyx continues to expect:

  • Total revenues of $31 million to $34 million
  • Total operating expenses of $41 million to $43 million, of which approximately $4 million is non-cash, stock-based compensation expense
  • Net loss of $8 million to $10 million
  • Basic and diluted net loss of $0.20 to $0.25 per share
  • Year-end cash, cash equivalents and investments available for sale balance greater than $30 million
  • Cash Status:"With approximately $40 million in cash and no debt, as well as approximately $28 million in anticipated additional license payments and research and development payments from collaborators, we continue to be well positioned from a financial standpoint to achieve our discovery, development and commercialization objectives and we have no plans to raise money through the issuance of equity or debt," Rogers concluded.

    In addition to its quarter-end cash balance, the Company has potential future sources of cash including the following:

  • $28 million from current collaborators for license fees and research and development funding
  • $30 million in potential milestone payments under current collaborations
  • $18 million related to a collaboration extension option
  • Conference Call:Senomyx will host a conference call at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) today to discuss these financial results and provide an update on the Company.  To participate in the live conference call, U.S. residents should dial (888) 680-0890, and international callers should dial (617) 213-4857, at least 10 min
    '/>"/>

    SOURCE Senomyx
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
    2. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
    3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
    4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
    5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    6. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    7. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    8. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    9. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    10. WuXi PharmaTech Announces Third-Quarter 2011 Results
    11. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... 29, 2015 Translation is frequently listed as ... a good reason--if used in a way that is right ... of a business product or service offering. , Here ... a positive effect on a company's bottom line: , 1.    Attract ... in the world can use, why not offer it globally? ...
    (Date:5/28/2015)... DUBLIN , May 28, 2015 ... Markets ( http://www.researchandmarkets.com/research/8h5hs2/animal ) has announced the ... "Animal Biotechnology - Technologies, Markets and ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This report describes and ... in veterinary medicine and pharmaceuticals as ...
    (Date:5/28/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has announced ... "Neuroprotection - Drugs, Markets and Companies" to ... role of neuroprotection in acute disorders such as ... well as in chronic diseases such as neurodegenerative ... damage to neural tissues are similar in all ...
    (Date:5/28/2015)... (PRWEB) May 28, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... the World Pork Expo, June 3-5 in Des ... year in a Wall Street Journal article because ...
    Breaking Biology Technology:Three Ways Translation Can Help Businesses Grow 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2
    ... Mass., Oct. 1 Based on the clinical ... today announced,that the company has expanded its executive ... MA. "The move to Massachusetts,allows us to consolidate ... Geoff Pardo. "It also gives us access to ...
    ... CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on,endocrine therapy and ... for the Company,s second efficacy trial of ... (BPH), a non-cancerous enlargement of the,prostate, with ...
    ... DUBLIN, Ireland, October 1 Shire Limited,(LSE: SHP, NASDAQ: ... approval by shareholders at the Annual General,Meeting on September ... Shire,plc with effect from today., Shire plc,s ticker ... ISIN numbers of the Company,s Ordinary shares and American ...
    Cached Biology Technology:Facet Solutions Establishes Corporate Headquarters and Expands Executive Team 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4
    (Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
    (Date:5/26/2015)... 2015 Research and Markets ... the "Saudi Arabia Biometric Systems Market Forecast ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market ... projected to grow at over 22% CAGR through ... to the surging demand for better biometric technologies ...
    (Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
    Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
    ... 18 October 2010, Singapore A total of 15 world ... in their respective fields at the 6th Decade of the ... 20 October 2010. Jointly organised by A*STAR,s Institute of ... (DRTech) and NUS,s Temasek Laboratories, it is the first such ...
    ... -- Harvard University neurobiologists have created mice that can "smell" ... better understand the neural basis of olfaction. The work, ... has implications for the future study of smell and of ... study with traditional methods. "It makes intuitive sense to ...
    ... 22 Lockheed Martin (NYSE: LMT ) and ... system that has potential to transform how law enforcement, homeland ... their missions. The prototype, called Rap I.D .™, ... special session on Rapid DNA. The day-long session is ...
    Cached Biology News:Singapore hosts first 'Decade of the Mind' conference in Asia 2Singapore hosts first 'Decade of the Mind' conference in Asia 3Mice that 'smell' light could help us better understand olfaction 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3
    ... The 1-D PAGE Cleavable ... for Targeted Protein ID ... PolyAcrylamide Gel Electrophoresis (PAGE), ... and cleavable-linker technology to ...
    Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
    Qa-1 (L-12)...
    ... , Coated Capture Antibody: 12 x 8-well strips, ... mL of 2X concentrate , Beta Amyloid ... , Lyophilized Standard Diluent: 3 mL , Primary ... Antibody-HRP: 30 microL of concentrate , OPD Substrate: ...
    Biology Products: